← Leaderboards
Vijay Chaitanya Ganta
University Of Virginia
$1,916,164
Attributed
$1,916,164
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $386.9K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,916,164 · 1
By mechanism
R01$1,916,164 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia
Same institution · by research overlap
- Mete Civelek$6,209,985
- Matthew James Gurka$3,986,980
- Craig S Nunemaker$3,563,425
- Jonathan R Lindner$23,863,903
- Karen-Kim E Innes$1,908,057
Others in their field
Other Emerging Leaders on “Disabling Symptom”
- Christopher Barnaby Nelson · University Of Melbourne$28,817,917
- Rene S. Kahn · Icahn School Of Medicine At Mount Sinai$16,796,818
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,144,108
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$14,031,836
- Burel R. Goodin · University Of Alabama At Birmingham$6,811,083
- Charles Bernick · Athira Pharma, Inc.$6,312,103
Research focus
Disabling SymptomDisease ModelAffinityDimerizationAcidsAlternative SplicingAmino AcidsArginineC-TerminalDiabetic MouseAngiogenesisBiopsyBlood FlowBlood VesselsCell-Free SystemCellsCell SurvivalChargeAspartic AcidClinical TrialsAmputationCoronaryBindingEdema
Grant awards (6)
A two amino acid switch in the anti-angiogenic VEGF165b isoform creates a novel agent for therapeutic angiogenesis in peripheral artery disease$379,864
R01 · FY2023 · HL · contact PI
A two amino acid switch in the anti-angiogenic VEGF165b isoform creates a novel agent for therapeutic angiogenesis in peripheral artery disease$380,299
R01 · FY2022 · HL · contact PI
A two amino acid switch in the anti-angiogenic VEGF165b isoform creates a novel agent for therapeutic angiogenesis in peripheral artery disease$385,000
R01 · FY2021 · HL · contact PI
A two amino acid switch in the anti-angiogenic VEGF165b isoform creates a novel agent for therapeutic angiogenesis in peripheral artery disease$384,063
R01 · FY2020 · HL · contact PI
A two amino acid switch in the anti-angiogenic VEGF165b isoform creates a novel agent for therapeutic angiogenesis in peripheral artery disease$284,897
R01 · FY2019 · HL · contact PI
A Two Amino Acid Switch in the Anti-angiogenic VEGF165b isoform creates a Novel Agent for Therapeutic Angiogenesis in Peripheral Artery Disease$102,041
R01 · FY2019 · HL · contact PI